PEN
What one share of Penumbra holds
Surgical and Medical Instruments and Apparatus
Penumbra, the world’s leading thrombectomy company, is focused on developing the most innovative technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism such as pulmonary embolism, and acute limb ischemia.
Penumbra’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $38.13 |
|---|---|
| Profit | $4.07 |
| Capex (buildings and equipment) | $1.57 |
| Free cash flow | $5.47 |
| Cash and investments | $5.21 |
| Book value | $38.86 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $7.87 | $0.44 | $0.41 | −$0.79 | — | $8.57 |
| 2017 | $9.45 | $0.13 | $0.35 | $0.00 | — | $11.89 |
| 2018 | $12.33 | $0.18 | $0.27 | $0.53 | — | $12.26 |
| 2019 | $15.09 | $1.34 | $0.61 | $0.13 | — | $13.88 |
| 2020 | $15.67 | −$0.44 | $0.69 | −$1.62 | — | $17.62 |
| 2021 | $19.74 | $0.14 | $0.56 | −$0.31 | — | $25.38 |
| 2022 | $22.39 | −$0.05 | $0.51 | −$1.98 | — | $26.21 |
| 2023 | $26.99 | $2.32 | $0.39 | $2.09 | — | $30.48 |
| 2024 | $30.42 | $0.36 | $0.54 | $3.75 | — | $29.90 |
| 2025 | $35.72 | $4.52 | $1.62 | $4.45 | — | $36.39 |